* CELLECTIS *
2000 - IDF
Romainville
(near Paris)
www.cellectis.com Discovery, Therapy
(also Research, Subcontractor)
Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair
Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.)
Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs
Competitors: Applied Biosystems, 454 Life Sciences, Celera
mail@cellectis.com
Age: 10 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Spin-off |
Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology]
Sc.Dir.-CSO: Pâques (Frédéric) [Ph.D. Sciences, Normale Sup (Ulm), ex-CNRS]
Fin.Dir.-CFO: Le Bozec (Marc) [HEC, ex-Alfact Innovation, Arthur D. Little, BioProtein (founder)]
BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO]
BusOff.: Dick Pollet [ex-Galapagos]
Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics]
Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis]
Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, Public | Turnover (M€) : 9.5 (2008), 1.2 (2006)
Total funding (M€) : 60.6
Last funding (M€) : 22.0
Focus : Genome
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .10 | Public offering (2nd) on Euronext : 22.0 M€ (1.914 Million new shares at 11.50 € each) | PBO | [9 years] |
| 2009 .10 | Acquisition of Vectocell Technology from Diatos assets (bankrupt in May 2009), to accelerate therapeutic development programs | ACQ+ | [9 years] |
| 2009 .09 | Set-up of Ectycell, a subsidiary specialized in stem cells from adults | ORGC | [9 years] |
| 2009 .06 | Launch of cGPS Custom, new kits for targeted gene integration in native cell lines, by affiliate Cellectis BioResearch | MKTG | [9 years] |
| 2008 .12 | Launch of PI10.3, a new research kit for producing stable cell clones using gene targeting in just 4 weeks, by affiliate Cellectis BioResearch | MKTG | [8 years] |
| 2008 .11 | Research : publication in Nature Magazine on a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis | R&D | [8 years] |
| 2008 .09 | Financing agreement by AFM (French Muscular Dystrophy Association), 8.3 M€ granted over 5 years for research on 7 genes surgery of orphan diseases | RFIN | [8 years] |
| 2008 .06 | Court : legal dispute on patents against Shionogi | LEGAL | [8 years] |
| 2008 .05 | Set-up of 2 new subsidiaries in France, Cellectis Bioresearch and Cellectis Genome Surgery | ORGC | [8 years] |
| 2007 .02 | Listing on Euronext Paris : 21.2 M€ | PBO | [7 years] |
| 2005 .06 | 3rd round-financing : 5.6 M€, by BankInvest, AGF P.E., Odyssée, Edmond de Rothschild (follow-up) | RFINC | [5 years] |
| 2004 .04 | Company move from Paris (Institut Pasteur) to Biocitech in Romainville | ORGL | [4 years] |
| 2002 .05 | 2nd round-financing : 8.0 M€, by BankInvest, AGF PE, Odyssée, Edmond de Rothschild | RFINB | [2 years] |
| 2000 .11 | 1st round-financing : 3.8 M€, by Kaminvest | RFINA | [0 year] |
| 2000 .06 | Licensing-in of 6 lead products from Institut Pasteur (spin-off with equity) | LICIN | [0 year] |
| 2000 .01 | Company founded by André Choulika and David Sourdive | ORGF | [0 year] | Actualisation / Updating: 08-Feb-2010 |
|
